Mandate

Vinge has advised Main Capital and Björn Lundén in connection with the acquisition of Due Compliance AB

Due Compliance is a software company which enables organisations to comply with the requirements in relation to Money Laundering and Terrorist Financing (Prevention) Act by providing digital tools for AML, KYC and Risk Assessments.

Björn Lundén, which is a strong provider of software for accounting, invoicing and payroll management, considers the acquisition of Due Compliance as an important step towards expanding its offering of digital tools in the regulatory market. The acquisition strengthens the group’s market position with the goal of becoming a leading player in Europe offering a comprehensive set of cloud-based accounting, ERP and RegTech solutions.
Vinge’s team consisted of Filip Öhrner, Josef Groow (M&A), Arvid Weimers, Karl-Gustaw Tobola, August Ahlin (Banking and Finance), Lisa Hörnqvist (IT and GDPR), Axel Lennartsson (IP), Victor Björkheim (employment) and Jessica Öijer (Transaction Support Senior Specialist).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025